title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Supplementary Information | The online version contains supplementary material available at 10.1186/s12913-023-10177-4. | PMC10621100 | ||
Keywords | PMC10621100 | |||
Background | readmission | CHRONIC DISEASES | Population ageing has turned into one of the most important public health challenges in recent years, a phenomenon that has affected Iran at a higher speed compared to other countries [Medication adherence is one of the challenges associated with polypharmacy in the elderly population. Medication adherence occurs when ... | PMC10621100 |
Methods | PMC10621100 | |||
Study design, sampling and data collection | death, cognitive diseases, diseases like cancer, insulin-dependent diabetic, COPD, diabetes | CARDIOVASCULAR DISEASE, CHRONIC DISEASES, COPD, HYPERTENSION, DIABETES | A randomized controlled trial study was conducted in April-June 2022. The research population consisted of older adults presenting to a hospital in Tehran, Iran. This hospital is a prominent health center for the geriatric population and has geriatric-specific clinics and services specializing in both acute and chronic... | PMC10621100 |
Intervention | In order to design the application used in this study, an in-depth review was conducted on the existing medication reminder application (both in Farsi and English) to identify their week points in order to solve these issues in new design. A drug management app compatible with android operating system with features suc... | PMC10621100 | ||
Data analysis | DISEASE | Data were entered into the SPSS software version 22 and analyzed according to per protocol using descriptive (frequency for number of chronic medications, mean for age, percentage and standard deviation for related categories) and inferential (Chi-square for sex, education level, income sufficiency, type of disease, ad... | PMC10621100 | |
Discussion | hypo, heart failure, hypertensive, readmission | ADVERSE EVENTS, DISEASE, HYPERGLYCEMIA, CONGESTIVE HEART FAILURE, HEART FAILURE, HYPERTENSION | The present study was conducted to evaluate the effect of using a drug management app on drug adherence and adverse events in polypharmacy adults. The results showed that using an app customized for the special conditions of the older adults improves medication adherence. In line with results of present study, Najafi e... | PMC10621100 |
Conclusion | ADVERSE EVENTS, DISEASE |
Considering that one of the basic goals of the health care system is to prevent the increase of costs and reduce the economic burden that is created by each individual and group of society, investigations such as the present study will provide valuable information about what policies should be implemented to achieve t... | PMC10621100 | |
Limitations | ADVERSE EVENTS |
There were some limitations in this study. Considering Morisky scale as a subjective tool to assess medication adherence, we used pill count method to avoid internal validity threat. This method was used as an objective and supplementary method, considering its practicality and simplicity. Lack of generalizability due... | PMC10621100 | |
Acknowledgements |
The current research is the result of a master’s thesis in geriatric nursing. We appreciate professor Morisky for giving us permission to use the MMAS-8-Item instrument. The researchers consider it necessary to express their gratitude to the Research Vice-Chancellor of the Faculty of Nursing and Midwifery of Tehran Un... | PMC10621100 | ||
Authors’ contributions | JJ |
HP: design of the study, implementation of study, drafting the manuscript; ShP: analysis and interpretation of data, drafting the manuscript; RN: design of the study, analysis and interpretation of the data, drafting the manuscript. JJ: designing the mobile application. All authors have read and approved the manuscrip... | PMC10621100 | |
Funding |
This research has been approved and supported by Tehran University of Medical Sciences and Health Services. | PMC10621100 | ||
Data availability |
All data generated in this study are included in the manuscript. Datasets are available upon reasonable request from the corresponding author. Mrs. Pashaeypoor is available for data and materials availability. The available e-mail address is Sh-Pashaeipour@tums.ac.ir. | PMC10621100 | ||
Declarations | PMC10621100 | |||
Ethical approval and consent to participate |
The study was approved by the Ethics Committee of Tehran University of Medical Sciences (IR.TUMS.FNM.REC.1400.068). It was also registered in the Iranian Registry of Clinical Trials (code: IRCT20191231045966N1) (18/07/2021). The participants were assured of data confidentiality and informed written consent was obtaine... | PMC10621100 | ||
Consent for publication | Not applicable. | PMC10621100 | ||
Competing interests | The authors declare no competing interests. | PMC10621100 | ||
References | PMC10621100 | |||
Subject terms | gingivitis | GINGIVITIS, GINGIVAL BLEEDING | To determine the effects on gingival bleeding, dental biofilm, and salivary flow and pH in patients with gingivitis of using toothpaste with extra-virgin olive oil (EVOO), xylitol, and betaine in comparison to a placebo or commercial toothpaste. This controlled, double blinded, and multicenter randomized clinical trial... | PMC10113385 |
Introduction | gingivitis | GINGIVAL BLEEDING, GINGIVITIS, CAVITY | The oral microbiome comprises all commensal, symbiotic, and pathogenic microorganisms present in the oral cavity and is made up of viruses, fungi, protozoa, archaea, and bacteria together with their habitat or ecosystem. At least 750 species of bacteria remain in eubiosis, i.e., in dynamic balance with the host immune ... | PMC10113385 |
Discussion | biofilm reduction, gingivitis, stinging, TNF-α | ADHESION, GINGIVITIS, GINGIVAL BLEEDING, PLAQUE | The main finding of this study was a reduction in gingival bleeding among patients with gingivitis who used a toothpaste with EVOO as main ingredient compared with those using a placebo toothpaste (control group 1). This result can be attributed to multiple biological mechanisms, with a potential role played by the com... | PMC10113385 |
Methods | bleeding, gingivitis, diabetes | PLAQUE, BLEEDING, GINGIVITIS, DIABETES | This multicenter, parallel-group, double-blind, placebo-controlled randomized clinical trial recruited patients from two primary healthcare centers (Loja and Huetor Tajar) in the province of Granada (Southern Spain) and from the Clinic of the School of Dentistry of Granada University from July 2021 until September 2022... | PMC10113385 |
Acknowledgements | This study was supported with a grant (STOP ORAL DYSBIOSIS Ref. OTRI-4907) awarded by the University of Granada and Mucosal Innovations S.L. (Madrid). | PMC10113385 | ||
Author contributions | Each author’s contribution is detailed as follows: Conception or design of the work: F.M. and A.R.A; Data acquisition: A.R.A., R.M. and J.F.; Data analysis: M.B.; Data interpretation: A.M.F. and A.L.T; Manuscript draft: F.M., A.R.A, A.M.F. All authors have revised and approved the final version of the manuscript. | PMC10113385 | ||
Data availability | The datasets analyzed during the current study are available from the corresponding author on reasonable request, considering the privacy and data protection. | PMC10113385 | ||
Competing interests | The authors declare no competing interests. | PMC10113385 | ||
References | PMC10113385 | |||
Abstract | PMC10202125 | |||
Background | PEANUT ALLERGY, TOLERANCE, PEANUT ALLERGY | The Learning Early About Peanut allergy (LEAP) study has shown the effectiveness of early peanut introduction in prevention of peanut allergy (PA). In the Enquiring About Tolerance (EAT) study, a statistically significant reduction in PA was present only in per‐protocol (PP) analyses, which can be subject to bias. | PMC10202125 | |
Objective | The aim of this study was to combine individual‐level data from the LEAP and EAT trials and provide robust evidence on the bias‐corrected, causal effect of early peanut introduction. | PMC10202125 | ||
Method | As part of the European Union‐funded iFAAM project, this pooled analysis of individual pediatric patient data combines and compares effectiveness and efficacy estimates of oral tolerance induction among different risk strata and analysis methods. | PMC10202125 | ||
Results | An intention‐to‐treat (ITT) analysis of pooled data showed a 75% reduction in PA ( | PMC10202125 | ||
Conclusion | allergy, eczema | ALLERGY, PEANUT ALLERGY, ECZEMA | We demonstrate a significant reduction in PA with early peanut introduction in a large group of pooled, randomized participants. This significant reduction was demonstrated across all risk subgroups, including children with no eczema. Furthermore, our results point to increased efficacy of the intervention with earlier... | PMC10202125 |
INTRODUCTION | eczema | INFECTIOUS DISEASES, PEANUT ALLERGY, ALLERGY, EGG ALLERGY, REGRESSION, PEANUT ALLERGY, ECZEMA | Despite strong findings favoring early peanut introduction, there are gaps in our knowledge base, especially with respect to whether to target high risk or normal populations and age of intervention. It is therefore not surprising that specialist organizations provide different guidelines regarding peanut introduction.... | PMC10202125 |
METHODS | atopy, allergy, Atopic Dermatitis, eczema | ATOPY, PEANUT ALLERGY, ATOPIC DERMATITIS, FOOD ALLERGY, ALLERGY, SECONDARY, ECZEMA | Study‐specific methods for the LEAP and EAT studies are published in full elsewhere and cohort demographics are summarized in Table The European Union‐funded iFAAM (Integrated Food Allergy and Allergen Management) project included a pooled analysis of individual‐level data from the RCTs of early allergenic food introdu... | PMC10202125 |
Statistical analysis | allergy | REGRESSION, ALLERGY, PEANUT ALLERGY | The primary endpoint of this pooled analysis was peanut allergy prevalence—defined on the basis of a positive oral food challenge (OFC) or sensitization and symptom history where food challenge was not done. Ninety‐one per cent of peanut allergy diagnoses were made on the basis of OFC. The primary analysis methodology ... | PMC10202125 |
RESULTS | eczema | PEANUT ALLERGY, ECZEMA | Individual‐level participant data from the EAT and LEAP studies were combined to give a pooled estimate of peanut allergy prevalence in intervention and control groups based on data from 1943 children. Demographic characteristics, eczema severity and baseline IgE sensitization were balanced between control and interven... | PMC10202125 |
Peanut allergy | allergic, peanut allergy | PEANUT ALLERGY, PEANUT ALLERGY | Peanut allergy status could be evaluated in 1796 of 1943 children in the LEAP and EAT cohorts; 86 of whom (4.8%) were allergic to peanut at 3–5 years of age (Table Peanut allergy prevalence at 3–5 years of age—(A) Intention‐to‐treat and (B) per‐protocol populations. Prevalence of peanut allergy in each randomized treat... | PMC10202125 |
Eczema | peanut allergy, eczema | PEANUT ALLERGY, PEANUT ALLERGY, ECZEMA | Participants with eczema at baseline contributed disproportionately to the prevalence of peanut allergy: 0.9% (8/900) in those with no eczema versus 8.7% (78/895) in those with eczema. The effect of early introduction in these eczema subgroups is key to determining the potential impact of any early introduction strateg... | PMC10202125 |
Peanut sensitization | peanut allergy | PEANUT ALLERGY, PEANUT ALLERGY | In both individual and pooled study results, skin prick test sensitization to peanut was significantly reduced at 12 months among those introducing peanut early in comparison with those avoiding or introducing them after 6 months of age. IgE sensitization to peanut at 12 months of age remained similar between the rando... | PMC10202125 |
Ethnicity | PEANUT ALLERGY | Non‐Caucasian groups combined (approximately 20% of all participants) had an approximately threefold higher prevalence of peanut allergy compared with Caucasians (16.8% vs 5.5%, | PMC10202125 | |
Causal effects | allergy, x‐axis | REGRESSION, ALLERGY, PEANUT ALLERGY | Due to lower protocol compliance in the EAT study, we implemented a causal inference approach to estimate the intervention's effect on peanut allergy. In pooled analyses adjusted for study, peanut consumption demonstrated statistically significant causal effects on peanut allergy prevalence. Under all causal inference ... | PMC10202125 |
Age of introduction | PEANUT ALLERGY | In an exploratory analysis, we examined the association between age of introduction of peanut and the prevalence of peanut allergy at 36 months in the EAT study (Figure Prevalence of peanut allergy by age of introduction to peanut in the EAT study. The prevalence of peanut allergy at 36 months is shown according to the... | PMC10202125 | |
DISCUSSION | ’, allergy, atopic, weakness, eczema | PEANUT ALLERGY, CARD, ALLERGY, ECZEMA, ATOPIC, REGRESSION, EGG ALLERGY | In order to maximize the use of data from the EAT and LEAP studies and assess the efficacy of intervention in important subgroups, we undertook a patient‐level meta‐analysis. The EAT study included participants with varying risk, while LEAP was limited to high‐risk participants. To account for these differences, we inc... | PMC10202125 |
AUTHOR CONTRIBUTIONS | Kirsty Logan, Henry T. Bahnson, Joanna Craven, Kirsten Beyer, Dianne E Campbell, E N Clare Mills and Gideon Lack conceptualized and designed the study. George Du Toit, Graham Roberts, Kirsty Logan, Michael R Perkin, Joanna Craven, Henry T. Bahnson, Ronald van Ree, E N Clare Mills, Johanna Bellach and Gideon Lack acquir... | PMC10202125 | ||
FUNDING INFORMATION | Allergy | INFECTIOUS DISEASES, FOOD ALLERGY, ALLERGY, ASTHMA | The main components of this analysis were funded by the European Union (Integrated Approaches to Food Allergen and Allergy Risk Management (iFAAM), Grant Agreement No: 312147). The EAT Study was jointly funded by the UK Food Standards Agency (FSA, contract code T07051) and the Medical Research Council (MRC, grant MC_G1... | PMC10202125 |
CONFLICT OF INTEREST | Pharma/Mylan, allergy | INFECTIOUS DISEASES, ALLERGY, FOOD ALLERGY, ALLERGY, ASTHMA, FOUNDER | HB reports grants from the National Institute of Allergy and Infectious Diseases (NIAID, NIH) and consulting fees from DBV Technologies, outside the submitted work. KB reports institutional grants from the European Union during the conduct of the study and lecture fees from Aimmune, Allergopharma, Bencard, Danone/Nutri... | PMC10202125 |
Supporting information | APPENDIX |
Appendix S1
Click here for additional data file. | PMC10202125 | |
ACKNOWLEDGMENTS | We thank Colin O'Rourke for his review and input of the statistical analyses of this manuscript and Andrew Leach for his assistance with the graphical abstract design. | PMC10202125 | ||
REFERENCES | PMC10202125 | |||
Abstract | CML | CHRONIC MYELOID LEUKEMIA, CML | Asciminib, a first‐in‐class, allosteric inhibitor of BCR‐ABL1 that acts by STAMP (Specifically Targeting the ABL Myristoyl Pocket), is a novel therapeutic option for patients with chronic myeloid leukemia (CML). In the global, phase 3, open‐label ASCEMBL study in patients with CML in chronic phase (CML‐CP) pretreated w... | PMC9939084 |
INTRODUCTION | Ph+, CML | MYELOPROLIFERATIVE NEOPLASM, PHILADELPHIA CHROMOSOME, CHRONIC MYELOID LEUKEMIA, CML, RECIPROCAL TRANSLOCATION | Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm defined by the presence of the Philadelphia chromosome (Ph), which is a result of reciprocal translocation of the Abelson (TKIs currently available in Japan include the first‐generation TKI imatinib, the second‐generation TKIs nilotinib, dasatinib, and bos... | PMC9939084 |
METHODS | PMC9939084 | |||
Ethics | The ASCEMBL study was conducted in accordance with the principles of the Declaration of Helsinki. An independent ethics committee or institutional review board at each center approved the study protocol. All patients provided written informed consent before the study initiation. | PMC9939084 | ||
Study design and patients | ELN | CHRONIC MYELOID LEUKEMIA | ASCEMBL is an ongoing, phase 3, global, multi‐center, open‐label, randomized, active‐controlled study (Figure ASCEMBL study design. CML‐CP, chronic myeloid leukemia in chronic phase; FPFV, First patient first visit; MCyR, major cytogenetic response; TKI, tyrosine kinase inhibitors. Key exclusion criteria were the prese... | PMC9939084 |
Treatments | Asciminib and bosutinib were taken orally as tablets. Asciminib was taken in the fasted state (fasting for at least 2 h before and at least 1 h after taking asciminib; water was permitted); bosutinib was taken with food. Concomitant medications deemed necessary for the supportive care of patients were permitted. Treatm... | PMC9939084 | ||
Endpoints | The primary endpoint in the ASCEMBL study was the rate of MMR ( | PMC9939084 | ||
Study assessments | Assessments of molecular, cytogenetic, and hematologic responses were performed as described previously | PMC9939084 | ||
Statistical analysis | ADVERSE EVENT | All Japanese patients who were randomized in the ASCEMBL study were included in the efficacy analysis (full analysis set, FAS). All Japanese patients who received at least one dose of study drug were included in the safety analysis (safety set). For efficacy endpoints, the rate and associated 95% CI (based on the Clopp... | PMC9939084 | |
RESULTS | PMC9939084 | |||
Participants' disposition | MAY | Overall, 16 patients in 10 sites in Japan were randomized in the ASCEMBL study to receive asciminib (Patient dispositionAbbreviation: NA, not applicable.Ongoing at the time of data cutoff: May 25, 2020.Patients could switch to asciminib upon meeting lack of efficacy criteria as per ELN 2013 recommendations on bosutinib... | PMC9939084 | |
Baseline characteristics ‐ asciminib group | Baseline characteristics of patients randomized to asciminib are shown in Table Demographics and baseline characteristicsAbbreviations: IS, international scale; MCyR, major cytogenetic response; TKI, tyrosine kinase inhibitor. | PMC9939084 | ||
Efficacy ‐ asciminib group | Efficacy results of patients randomized to asciminib are shown in Figure Efficacy endpoints at week 24 in Japanese patients randomized to Asciminib in the ASCEMBL study. | PMC9939084 | ||
Baseline characteristics and efficacy ‐ bosutinib group | Description of the baseline characteristics (Table | PMC9939084 | ||
Safety | ADVERSE EVENT | Median duration of exposure to study treatment was 44.9 (range, 20.1–101.6) weeks for asciminib and 3.1 (range, 1.3–29.0) weeks for bosutinib. Overall, 10 (76.9%) patients in the asciminib group, and 3 (100.0%) patients in the bosutinib group experienced at least 1 AE (any grade) during the study (Table Adverse events ... | PMC9939084 | |
DISCUSSION | CML | CML | ASCEMBL is the first randomized, controlled study in patients with CML‐CP who have been previously treated with TKIs. In the primary analysis of the overall study population, asciminib demonstrated a statistically significant clinical benefit versus bosutinib, meeting the primary study endpoint with an almost two times... | PMC9939084 |
CONCLUSION | Efficacy and safety results observed with asciminib in this Japanese subgroup are comparable to those previously reported for the overall study population in the ASCEMBL study. The findings support asciminib as a new therapeutic option for Japanese patients with CML‐CP after prior treatment with TKIs. | PMC9939084 | ||
AUTHOR CONTRIBUTIONS | All authors were involved in the designing of the study, collection, analysis, and interpretation of data. All authors contributed to the drafting and reviewing of the manuscript and provided final approval of the version to be published. | PMC9939084 | ||
FUNDING INFORMATION | This study was sponsored by Novartis Pharma K.K.(Japan). | PMC9939084 | ||
CONFLICT OF INTEREST | Naoto Takahashi has received honoraria from Pfizer, Otsuka, and Novartis; research funding from Pfizer, Otsuka, Novartis, Chugai, Eizai, Asahikasei, Ono, and Kyowahakko‐Kirin outside the submitted work. Yosuke Minami received research funding from Ono and CMIC, and honoraria from Bristol‐Myers Squibb, Novartis, Astella... | PMC9939084 | ||
Supporting information | APPENDIX |
Appendix S1
Click here for additional data file. | PMC9939084 | |
ACKNOWLEDGMENTS | Cancer | INFECTIOUS DISEASES, CROSS, CANCER | The authors thank Himabindu Gutha, PhD, of Novartis Healthcare Pvt Ltd, Hyderabad, India, for providing medical writing and editorial support for the manuscript. The authors thank the patients and their families, and investigators and staff at each participating study site: National Cancer Center Hospital East; Tokyo M... | PMC9939084 |
DATA AVAILABILITY STATEMENT | Novartis is committed to sharing with qualified external researchers access to patient‐level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel based on scientific merit. All data provided are anonymized to respect the privacy of patient... | PMC9939084 | ||
REFERENCES | PMC9939084 | |||
Background | Adoption of health-enabling food retail interventions in food retail will require effective implementation strategies. To inform this, we applied an implementation framework to a novel real-world food retail intervention, the Healthy Stores 2020 strategy, to identify factors salient to intervention implementation from ... | PMC9938595 | ||
Methods | A convergent mixed-method design was used and data were interpreted using the Consolidated Framework for Implementation Research (CFIR). The study was conducted alongside a randomised controlled trial in partnership with the Arnhem Land Progress Aboriginal Corporation (ALPA). Adherence data were collected for the 20 co... | PMC9938595 | ||
Results | Healthy Stores 2020 strategy was, for the most part, adhered to. Analysis of the 30 interviews revealed that implementation climate of the ALPA organisation, its readiness for implementation including a strong sense of social purpose, and the networks and communication between the Store Managers and other parts of ALPA... | PMC9938595 | ||
Conclusions | Factors critical to implementation (a strong sense of social purpose; structures and processes within and external to the food retail organisation and their alignment with intervention characteristics (low complexity, cost advantage); and Store Manager characteristics) can inform the design of implementation strategies... | PMC9938595 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12966-022-01377-y. | PMC9938595 | ||
Keywords |
There is a paucity of evidence on what implementation strategies can enhance the uptake of empirical evidence into food retail practice for public health gain.We found through evaluation of a multi-store food retail intervention randomised controlled trial that implementation was influenced by multiple contextual fact... | PMC9938595 | ||
Background | DISEASE | Dietary factors, such as low fruit, vegetable and fibre intake, and high sodium and sugar sweetened beverage intake, are leading modifiable contributors to the global burden of disease [Multicomponent interventions using behaviour change communication techniques in combination with modification of the store architectur... | PMC9938595 | |
Method | PMC9938595 | |||
Aim and design | This study was conducted alongside a pragmatic RCT aimed to test the effectiveness of the Healthy Stores 2020 strategy in achieving a reduction in free sugars to energy that is reported elsewhere [ | PMC9938595 | ||
Theoretical framework | We approached this study from a social constructivist position [ | PMC9938595 | ||
Study setting | This study was conducted in partnership with ALPA, a private sector not-for-profit business and Australia’s largest Indigenous corporation [ | PMC9938595 | ||
Store governance | Store Boards in the ALPA owned and ALPA managed stores set policies and procedures for their stores. Store Managers of ALPA owned and/or managed stores (whom are mostly non-Indigenous and not from the communities) are employed by ALPA and governed by ALPA policies and procedures. Managers are responsible for stock orde... | PMC9938595 | ||
Study context | Sugar reduction | The partnership with ALPA for this study stemmed from a long, over two-decade relationship between a number of the research team members and ALPA. ALPA has a strong social purpose and developed a Health and Nutrition strategy in the 1980s for its stores and has since subsidised the freight cost on fruit and vegetables ... | PMC9938595 | |
Recruitment of stores for Healthy Stores 2020. | All 25 stores owned and/or managed by ALPA at the time of the study were invited to participate. Twenty stores across 19 communities consented to participate and were then randomised to intervention and control groups, as previously described [ | PMC9938595 | ||
Participant characteristics | Participants for the study described herein were the 20 consenting stores (for adherence data) and each primary Store Manager for each of the ten intervention stores at the time of data collection (for retailer experience data). | PMC9938595 | ||
Implementation | ALPA were responsible for the implementation of the Healthy Stores 2020 strategy in their stores. A visiting team of two to three people that comprised an ALPA staffer/s and/or a research team member set-up the intervention in each of the ten intervention stores with the input of the Store Managers and the assistance o... | PMC9938595 | ||
Data collection | Adherence to each strategy component was assessed using an adherence checklist applied fortnightly by a research team member (EC) via fortnightly phone-interview with Store Managers at a time of their convenience to check adherence (Additional file Table Retailer experience was assessed using semi-structured interviews... | PMC9938595 | ||
Results | Adherence checklists and photographic material were collected for all 20 stores. A total of 30 interviews were conducted with some changeover of Store Managers throughout this period. A summary of themes by the CFIR constructs, including constructs with no supporting data, are presented in Table | PMC9938595 | ||
Retailer implementation experiences | PMC9938595 | |||
Discussion | This research provides an in-depth analysis of the factors that operated within and external to the Store Managers to influence the implementation of a novel healthy food retail intervention during a 12-week trial of its efficacy. Factors in each of the five CFIR domains were identified to be important, as was their al... | PMC9938595 | ||
Strengths and limitations | This study uses real-world data to advance knowledge on factors that influenced the implementation of the Healthy Stores 2020 strategy from the perspective of Store Managers responsible for the strategy’s day-to-day implementation. Our use of a well-recognised implementation framework, the CFIR, and consideration of al... | PMC9938595 | ||
Implications for research and practice | We previously demonstrated the effectiveness of the Healthy Stores 2020 intervention and its resultant impact on reducing sales of free sugars [There are over 200 food retail stores in very remote Australia and there are factors common to these store contexts, such as community need, that suggest a potential strong fit... | PMC9938595 | ||
Conclusion | This research provides an in-depth analysis of strategy adherence and the factors operating within and external to the Store Managers of the remote community stores that influenced the implementation of the Healthy Stores 2020 strategy. Multiple factors found to operate within each of the CFIR domains, impacted impleme... | PMC9938595 | ||
Acknowledgements | DIAZ, BROWN | We acknowledge the Arnhem Land Progress Aboriginal Corporation (ALPA) board of directors, retail leadership team, ALPA store managers and directors of ALPA-managed stores. We acknowledge the contribution of the store managers specifically for providing interview and other data and the Healthy Stores 2020 working group ... | PMC9938595 | |
Authors’ contributions | KDS, CM | All authors contributed to study design, interpretation and manuscript writing. JB led the study and wrote the manuscript. EC collected interview data and collected and analyzed adherence data. AG assisted with adherence data analysis. BM coded and analyzed interview data and prepared results with JB and drafted the me... | PMC9938595 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.